Cipla Ltd

Large Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Cipla announced that its Bengaluru facility received a Voluntary Action Indicated classification from the USFDA following a May inspection. The company reported a 10.18% increase in Q1 FY26 net profit, emphasizing its commitment to compliance and addressing any observations noted by the FDA.

Cipla's Bengaluru Facility Receives VAI Classification - 05 Aug, 2025

Cipla has opened a window for physical share transfers and allotted equity shares under employee schemes. The company is also focusing on GLP-1 therapy opportunities with a strategy tailored for India's market.

Cipla Engages Shareholders and Targets GLP-1 Market - 03 Aug, 2025

Cipla's stock is experiencing bullish momentum with multiple analysts raising price targets. ICICI Securities targets Rs 1,800, while Jefferies raises its target to Rs 1,690. The company is expected to offset subdued US sales with new product launches and strong performance in chronic therapy segments.

Cipla Stock Shows Bullish Momentum and Target Increases - 29 Jul, 2025

Cipla's share price has broken out of a falling channel pattern, indicating a long buildup. With strong support at ₹1,500 and targets of ₹1,600/1,650, the stock shows a positive bias and potential upside.

Cipla Stock Shows Positive Momentum - 26 Jul, 2025

Cipla's Q1 FY26 results show a 10.2% increase in net profit to ₹1,298 crore, driven by strong performance in generics and consumer health. Revenue rose to ₹6,837 crore. The company anticipates significant opportunities in the GLP-1 drug market as patents expire. Cipla's stock rose by approximately 3% following the earnings announcement.

Cipla Reports Strong Q1 FY26 Earnings Growth - 25 Jul, 2025

Cipla is set to announce Q1FY26 earnings with moderate growth expectations. Revenue may rise 5.6% YoY, while profit growth is limited. The company reported strong FY25 results, with Foracort as a top-selling brand. However, profitability faces pressure from muted US sales and pricing challenges.

Cipla's Q1FY26 Preview Shows Growth Amid Challenges - 23 Jul, 2025

Cipla Ltd has signed agreements to acquire a 20% stake in iCaltech Innovations for ₹5 crore, focusing on expanding its presence in respiratory diagnostics and medical devices.

Cipla Invests in iCaltech Innovations for Growth - 21 Jul, 2025

Cipla Limited appointed BNP & Associates as Secretarial Auditors for five years, approved by shareholders at the 89th AGM. This move is expected to boost investor confidence. Additionally, sell flows from institutions and weaker Q1FY26 earnings expectations were noted.

Cipla Strengthens Governance with New Auditor Appointment - 17 Jul, 2025

Cipla is expanding its dermatology product line while completing a significant asthma study, enhancing its market position. Chairman YK Hamied emphasizes future investments and focus areas.

Cipla's Strategic Expansion and Study Completion - 16 Jul, 2025

Cipla is set to enter India's weight management market, addressing rising obesity demands while enhancing its central nervous system portfolio through strategic acquisitions and in-licensing deals.

Cipla Ventures into Weight Management Market - 13 Jul, 2025

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

Netprofit is up for the last 2 quarters, 1.22K Cr → 1.29K Cr (in ₹), with an average increase of 5.8% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Spike

Revenue is up for the last 2 quarters, 7.01K Cr → 7.21K Cr (in ₹), with an average increase of 2.7% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Rich

In the last 1 year, Divis Laboratories Ltd has given 34.4% return, outperforming this stock by 34.4%

This section gives you an insight into how the peers have performed as compared to this company in the last 1 year.

Against Peers

In the last 3 years, Torrent Pharmaceuticals Ltd has given 132.1% return, outperforming this stock by 85.6%

This section gives you an insight into how the peers have performed as compared to this company in the last 3 years.

Promoters holdings remained unchanged at 29.13% of holdings in Jun 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Unchanged

Foreign Institutions have decreased holdings from 26.22% to 25.19% in Jun 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Down

Mutual Funds have decreased holdings from 20.47% to 20.40% in Jun 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Down

In the last 7 days, CIPLA stock has moved down by -3.7%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Dip

Retail Investor have decreased holdings from 16.33% to 16.27% in Jun 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Down

BSE 100

Nifty Healthcare

Nifty50 Value 20

NIFTY 100

S&P BSE 100 LargeCap TMC

BSE 200

Nifty100 Low Volatility 30

S&P BSE Dividend Stability

Nifty100 Eq Weig

S&P BSE Largecap

BSE Healthcare

S&P BSE 100 ESG

S&P BSE 250 LargeMidCap

NIFTY PHARMA

BSE 500

Nifty 200

S&P BSE SENSEX 50

BSE MFG

NIFTY 50

Nifty LargeMidcap 250

Nifty 500

HDFC Flexi Cap Fund -Direct Plan - Growth Option

Parag Parikh Flexi Cap Direct Growth

SBI ELSS Tax Saver Fund Direct Growth

HDFC ELSS TaxSaver -Direct Plan - Growth Option

HDFC Focused Fund -Direct Plan - Growth Option

Cipla's Bengaluru facility receives VAI classification from USFDA after May inspection, indicating some issues but no serious regulatory action.

Cipla Ltd’s net profit jumped 10.19% since last year same period to ₹1,297.62Cr in the Q1 2025-2026. On a quarterly growth basis, Cipla Ltd has generated 6.2% jump in its net profits since last 3-months.

Name	Value	Action
MACD level (12,26)	0.71	Bearish
CCI (20)	214.62	Bearish
RSI (14)	43.77	Neutral
Momentum (10)	-1.8	Bearish
ADI (14)	38.73	Bearish
Ultimate Oscillator (7,14,28)	36.2	Neutral

Name	Value	Action
SMA (20)	1500.61	Bearish
EMA (20)	1500.27	Bearish
VWMA (20)	1500.77	Bearish
SMA (50)	1498.17	Bullish
EMA (50)	1498.75	Bullish
SMA (200)	1496.61	Bullish
EMA (200)	1498.09	Bullish
KAMA (200)	1498.42	Bullish
DEMA (200)	1495.62	Bullish

Cipla Ltd (CIPLA)

Summary

Overall

Oscillators

Moving Averages